Regulatory Affairs

ARTICLES

Canadian Drug Regulators Unveil Fee Increases

Health Canada has proposed fee hikes for reviewing applications for approval of new drugs, for oversight of drug manufacturing facilities, for postmarket monitoring of drug sales and for other regulatory activity. Read More

OMB Mulls One-Year Delay of Common Rule Revision

The White House’s Office of Management and Budget (OMB) proposes to delay for one year, until January 2019, the effective date of a revision to the sweeping Common Rule that governs federal policy on the use of human subjects in clinical trials. Read More

PRODUCTS

Advertising Drugs and Devices: Keys to FDA and FTC Compliance

$177.00
Advertising Drugs and Devices: Keys to FDA and FTC Compliance, a hands-on guide, lays out the advertising landscape as the government sees it — regulations, requirements, expectations — and shows you the right road to take to compliance. View

ICH E6 R2 - Webinar Recording/Transcript

$287.00
The ICH E6 R2 GCP guideline has major impact on everyone from clinical trial principal investigators to drug and biologics makers. But a year after its promulgation, clinical trials professionals still struggle with its provisions. View

The U.S. Opioid Crisis - Webinar Recording/Transcript

$287.00
The opioid crisis is the stuff of daily headlines. But behind the headlines lurk serious implications for drugmakers, healthcare providers and other regulated firms. View

Must-Know Contracting for Non-Lawyers - Webinar Recording/Transcript

$287.00
When it comes to supply contracts, it’s far better to do things right going in ... rather than pay the price down the road. In just 90 fast-moving minutes, Courtney Young Esq. of MedMarc Insurance Group walks you through the essentials of supply contracts — what to include, what to (safely) leave out, how to stand up for yourself. View

Expanded Access at a Crossroads - Webinar Recording/Transcript

$287.00
Expanded Access is the hottest topic in new-drug development, and now the FDA appears ready to loosen the reins. View

Supplier Assessment Checklists: A Tool for Vetting Vendors and Contractors

$197.00
Report includes two checklists that guide you through the process so that you don’t have to worry about missing any points or asking the wrong questions. View

Global Regulation Under Gottlieb-Trump and a Look Ahead - Webinar Recording/Transcript

$287.00
In Part IV of FDAnews’s Expert Insight Series, our panelists look overseas to evaluate drug and device regulation globally, and venture educated guesses concerning the direction of drug and device regulation in 2018 and beyond. View

Pharmaceutical Regulation Under Gottlieb-Trump - Webinar Recording/Transcript

$287.00
In Part III of FDAnews’s Expert Insight Series, our panel takes up drug regulation, policy and enforcement. View

Device Regulation Under Gottlieb & Trump - Webinar Recording/Transcript

$287.00
In Part II of FDAnews’s Expert Insight Series, our panel dives deep into device regulation, policy and enforcement. View

What We’ve Learned Since Scott Gottlieb Was Confirmed - Webinar Recording/Transcript

$287.00
FDAnews has assembled a standout panel — five top experts, four of them ex-FDAers — to bring their insights to bear on how the Gottlieb FDA will impact your products and programs. View

Promotional Communication: Keeping Up with FDA’s Off-Label Use Policy

$397.00
Promotional Communication: Keeping Up with FDA’s Off-Label Use Policy explores the draft guidances and other FDA activity on the subject of promotional communication — explaining what companies must do to stay on the right side of the agency’s new policies and how to take advantage of the opportunities they present. View

Advertising Medical Products - Webinar CD/Transcript

$287.00
Some drug and device TV ads earn fortunes. Others cost fortunes — in judgments, penalties and legal fees, hassles and wasted time, and lost reputation. Here’s how to tell one from the other. View